03/01/21 11:15 AMNASDAQ : VRPXDouble Milestone Payment Strengthens Nanomerics' Balance Sheet and Enables Nanomerics to Further Clinical ProgrammesNanomerics Ltd., a world leader in molecular engineered delivery technologies, today announced that the Company had received its first milestone payments from Virpax Pharmaceuticals (NASDAQ:VRPX). These milestone payments relate to the licensing of Envelta(TM)RHEA-AIpositive
02/23/21 8:00 AMNASDAQ : VRPXVirpax Begins IND Enabling Studies of Envelta(TM)Virpax (R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), today announced that according to the Cooperative Research and Development Agreement ("CRADA") entered into between Virpax and the National Center for Advancing TranslationalRHEA-AIpositive
02/19/21 4:07 PMNASDAQ : VRPXVirpax Pharmaceuticals Announces Closing of Initial Public OfferingVirpax Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the closing of its initial public offering of 1,800,000 shares of its commonRHEA-AIneutral
02/16/21 7:45 PMNASDAQ : VRPXVirpax(R) Pharmaceuticals Announces Pricing of Initial Public OfferingVirpax (R) Pharmaceuticals Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing pharmaceutical products for pain management, today announced the pricing of its initial public offering of 1,800,000 shares of its commonRHEA-AIneutral
